Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295828542> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4295828542 endingPage "S1073" @default.
- W4295828542 startingPage "S1072" @default.
- W4295828542 abstract "1L ICI combination therapy has transformed the tx paradigm for non-oncogene-addicted NSCLC. Acquired resistance to ICI therapy could be influenced and reversed by the use of subsequent anti-angiogenic therapy. In this setting, non-interventional data may help to guide post-progression therapeutic decision making. We therefore examined tx outcomes with 2L NIN + DOC with respect to response to 1L ICI combination therapy, and performance status (ECOG PS) at baseline. In this analysis of Cohort C of the ongoing, non-interventional VARGADO study (NCT02392455), eligible pts had locally advanced, metastatic or locally recurrent adenocarcinoma NSCLC and received 2L NIN + DOC in routine clinical practice after failure on 1L ICI combined with chemotherapy. The primary endpoint is 1-year survival rate (not yet mature). Tumour response was according to investigator review. In 176 pts enrolled in Cohort C, median age was 63 years (range: 37–84), 106 pts (60.2%) were men, 138 pts (78.4%) had an ECOG PS 0–1, and 157 pts (89.2%) had received prior 1L pembrolizumab-based combination therapy. In the overall population, objective response rate and disease control rate with 2L NIN + DOC were 35.0% (42/120 pts) and 68.3% (82/120 pts), respectively. Median PFS was 4.8 months (95% CI: 3.5–5.3) and no clear differences were seen with respect to best response to 1L therapy. Median OS was 8.1 months (95% CI: 6.3–11.2) in the overall population. There was a possible association between OS benefit with 2L tx and partial response (PR) as best response to 1L therapy (median OS 9.1 months [95% CI: 5.4–18.3]) especially in those pts with ECOG PS 0–1 (median OS 11.2 months [95% CI: 5.2–21.0]). Our results support 2L NIN + DOC as an effective tx option in pts with advanced adenocarcinoma NSCLC following 1L ICI combination therapy. Best response to 1L tx and ECOG PS may be valuable surrogate markers associated with clinical benefit of 2L NIN + DOC. These findings warrant further evaluation of the effect of these parameters on 2L tx outcomes after 1L ICI combination therapy." @default.
- W4295828542 created "2022-09-15" @default.
- W4295828542 creator A5009536191 @default.
- W4295828542 creator A5015898233 @default.
- W4295828542 creator A5024282182 @default.
- W4295828542 creator A5032314001 @default.
- W4295828542 creator A5040589443 @default.
- W4295828542 creator A5041857102 @default.
- W4295828542 creator A5046388207 @default.
- W4295828542 creator A5054452931 @default.
- W4295828542 creator A5072140218 @default.
- W4295828542 creator A5074420045 @default.
- W4295828542 creator A5079085915 @default.
- W4295828542 creator A5087787245 @default.
- W4295828542 date "2022-09-01" @default.
- W4295828542 modified "2023-10-01" @default.
- W4295828542 title "1143P Effect of best response to first-line (1L) treatment (tx) on outcomes with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after 1L immune checkpoint inhibitor (ICI) combination therapy" @default.
- W4295828542 doi "https://doi.org/10.1016/j.annonc.2022.07.1267" @default.
- W4295828542 hasPublicationYear "2022" @default.
- W4295828542 type Work @default.
- W4295828542 citedByCount "0" @default.
- W4295828542 crossrefType "journal-article" @default.
- W4295828542 hasAuthorship W4295828542A5009536191 @default.
- W4295828542 hasAuthorship W4295828542A5015898233 @default.
- W4295828542 hasAuthorship W4295828542A5024282182 @default.
- W4295828542 hasAuthorship W4295828542A5032314001 @default.
- W4295828542 hasAuthorship W4295828542A5040589443 @default.
- W4295828542 hasAuthorship W4295828542A5041857102 @default.
- W4295828542 hasAuthorship W4295828542A5046388207 @default.
- W4295828542 hasAuthorship W4295828542A5054452931 @default.
- W4295828542 hasAuthorship W4295828542A5072140218 @default.
- W4295828542 hasAuthorship W4295828542A5074420045 @default.
- W4295828542 hasAuthorship W4295828542A5079085915 @default.
- W4295828542 hasAuthorship W4295828542A5087787245 @default.
- W4295828542 hasBestOaLocation W42958285421 @default.
- W4295828542 hasConcept C121608353 @default.
- W4295828542 hasConcept C126322002 @default.
- W4295828542 hasConcept C141071460 @default.
- W4295828542 hasConcept C143998085 @default.
- W4295828542 hasConcept C203092338 @default.
- W4295828542 hasConcept C2776694085 @default.
- W4295828542 hasConcept C2776999253 @default.
- W4295828542 hasConcept C2777701055 @default.
- W4295828542 hasConcept C2778822529 @default.
- W4295828542 hasConcept C2779984678 @default.
- W4295828542 hasConcept C2780057760 @default.
- W4295828542 hasConcept C2781190966 @default.
- W4295828542 hasConcept C2908647359 @default.
- W4295828542 hasConcept C535046627 @default.
- W4295828542 hasConcept C71924100 @default.
- W4295828542 hasConcept C72563966 @default.
- W4295828542 hasConcept C99454951 @default.
- W4295828542 hasConceptScore W4295828542C121608353 @default.
- W4295828542 hasConceptScore W4295828542C126322002 @default.
- W4295828542 hasConceptScore W4295828542C141071460 @default.
- W4295828542 hasConceptScore W4295828542C143998085 @default.
- W4295828542 hasConceptScore W4295828542C203092338 @default.
- W4295828542 hasConceptScore W4295828542C2776694085 @default.
- W4295828542 hasConceptScore W4295828542C2776999253 @default.
- W4295828542 hasConceptScore W4295828542C2777701055 @default.
- W4295828542 hasConceptScore W4295828542C2778822529 @default.
- W4295828542 hasConceptScore W4295828542C2779984678 @default.
- W4295828542 hasConceptScore W4295828542C2780057760 @default.
- W4295828542 hasConceptScore W4295828542C2781190966 @default.
- W4295828542 hasConceptScore W4295828542C2908647359 @default.
- W4295828542 hasConceptScore W4295828542C535046627 @default.
- W4295828542 hasConceptScore W4295828542C71924100 @default.
- W4295828542 hasConceptScore W4295828542C72563966 @default.
- W4295828542 hasConceptScore W4295828542C99454951 @default.
- W4295828542 hasLocation W42958285421 @default.
- W4295828542 hasOpenAccess W4295828542 @default.
- W4295828542 hasPrimaryLocation W42958285421 @default.
- W4295828542 hasRelatedWork W1942080391 @default.
- W4295828542 hasRelatedWork W2234542209 @default.
- W4295828542 hasRelatedWork W2557996697 @default.
- W4295828542 hasRelatedWork W2738397398 @default.
- W4295828542 hasRelatedWork W2766168689 @default.
- W4295828542 hasRelatedWork W2974072238 @default.
- W4295828542 hasRelatedWork W3177224496 @default.
- W4295828542 hasRelatedWork W3213977202 @default.
- W4295828542 hasRelatedWork W4281568334 @default.
- W4295828542 hasRelatedWork W4322775203 @default.
- W4295828542 hasVolume "33" @default.
- W4295828542 isParatext "false" @default.
- W4295828542 isRetracted "false" @default.
- W4295828542 workType "article" @default.